|
Download
PDF
|
Biosimilars: Benchmarking the key
players - With increasing regulatory clarity and high revenue
potential, interest in biosimilars increases
With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.
View
Table Of Contents >
|
